Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Last trade$93.58
Day change-$5.795 (-5.83%)
Day range$85.71 – $100.97
Volume680,981
Market cap$9.44B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$9.44B
Price / earnings
—
Price / book
8.97×
Price / sales
—
EV / sales
—
EV / EBITDA
-29.22×
Profitability
Earnings per share
-$2.36
Return on assets
-20.38%
Return on equity
-21.31%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
27.4×
Quick ratio
27.4×
Cash ratio
2.06×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$249.32M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SYRE, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$16.55M
$16.14M
$15.23M
$12.53M
$11.64M
$11.79M
$11.94M
$10.77M
Research and development
$89.17M
$65.5M
$60.41M
$44.64M
$45.25M
$40.15M
$41.62M
$50.48M
Total operating expenses
$105.72M
$81.64M
$75.64M
$57.17M
$56.89M
$51.94M
$53.57M
$61.25M
Operating income
-$105.72M
-$81.64M
-$75.64M
-$57.17M
-$56.89M
-$51.94M
-$53.57M
-$61.25M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$96.12M
-$36.2M
-$69.01M
-$62.53M
-$11.18M
-$36.72M
-$44.79M
-$56.3M
Income taxes
$0
$0
$0
$0
$0
$0
-$15K
$1K
Net income
-$96.12M
-$36.2M
-$69.01M
-$62.53M
-$11.18M
-$36.72M
-$44.77M
-$56.3M
Net income attributable to common shareholders
-$83.11M
-$30.92M
-$58.25M
-$51.83M
-$9.02M
-$29.6M
-$36.09M
-$43.67M
EBITDA
-$105.72M
-$81.64M
-$75.64M
-$57.17M
-$56.89M
-$51.94M
-$53.57M
-$61.25M
Basic earnings per share
-$0.94
-$0.36
-$0.74
-$0.69
-$0.15
-$0.49
-$0.60
-$0.79
Diluted earnings per share
-$0.94
-$0.36
-$0.74
-$0.69
-$0.15
-$0.49
-$0.60
-$0.79
Recent news
Company coverage with links to the original publishers.
Spyre Therapeutics announced presentations of clinical and preclinical data for its three IBD antibodies (SPY001, SPY002, and SPY003) at UEGW 2026 in Barcelona. The company presented efficacy and safety data for these half-life extended antibodies in moderately to severely active ulcerative colitis, along with preclinical evidence showing additive efficacy of combination approaches. The SKYLINE study is testing these candidates as monotherapies and pairwise combinations, with combination results expected in 2027.
Spyre Therapeutics priced its underwritten public offering at $85 per share, raising approximately $350 million in gross proceeds. The company plans to use the funds to advance its immunology programs in gastroenterology, rheumatology, and dermatology, including Phase 3 readiness and development of SPY072 for hidradenitis suppurativa. The offering is expected to close on October 7, 2026.
Spyre Therapeutics shares have declined 16.6% since its Q2 2026 earnings report, underperforming the S&P 500. The company reported a narrower-than-expected loss of 36 cents per share and benefited from a $40 million gain on asset sales, though R&D expenses surged 63.2% year-over-year. With $1.15 billion in cash expected to fund operations into late 2029, analyst estimates have shifted downward by 10.44%, and the stock holds a Zacks Rank #3 (Hold) rating.
Spyre Therapeutics priced an underwritten public offering of 6.5 million shares at $62.00 per share, generating approximately $403 million in gross proceeds. The offering is expected to close on April 16, 2026. Joint book-running managers include Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities, LLC.
Spyre Therapeutics, a clinical-stage biotechnology company focused on inflammatory bowel disease treatments, announced a proposed underwritten public offering of $300 million in common stock, with an additional $45 million option for underwriters. The offering is subject to market conditions and regulatory approval, with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities serving as joint book-running managers.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.